Drugs / Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)
Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02488070 | Jun → Aug 2015 | prostate carcinoma | Stanford University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02488070 ↗ |
| Known as | (68)Ga-PSMA-11 | “Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] ((68)Ga-PSMA-11) is a PET tracer that can detect prostate cancer relapses and metastases by binding to the extracellular domain of PSMA.” PMID 26659347 ↗ Dec 2015 |
| Known as | Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] | “Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] ((68)Ga-PSMA-11) is a PET tracer that can detect prostate cancer relapses and metastases by binding to the extracellular domain of PSMA.” PMID 26659347 ↗ Dec 2015 |
| Modality | Diagnostic / imaging agent | “is a PET tracer that can detect prostate cancer relapses and metastases” PMID 26659347 ↗ Dec 2015 |
| Route | Intravenous | “Patients are injected with 5 mCi of Ga68 PSMA intravenously (IV)” NCT02488070 ↗ |